USPTO serial 97339107
WELLNESS BY DESIGN
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- NGUYEN, CINDY EVANS
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with WELLNESS BY DESIGN?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
THOMAS J. ROMANO
THOMAS J. ROMANO KOLITCH ROMANO DASCENZO GATES LLC621 SW MORRISON STREET #1100PORTLAND, OR 97205UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical agents affecting digestive organs; Pharmaceutical agents affecting metabolism; Pharmaceutical agents affecting sensory organs; Pharmaceutical antitussive-cold preparations; Pharmaceutical preparation for skin care; Pharmaceutical preparations for skin care; Pharmaceutical preparations for skin wounds; Pharmaceutical preparations for suppressing tumors; Pharmaceutical preparations for the central nervous system; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, and for the treatment of diabetes, and anti - infective preparations, antiviral preparations, antibiotics, antifungal preparations and vaccines; Pharmaceutical preparations for the prevention of thrombosis; Pharmaceutical preparations for the treatment of autoimmune diseases; Pharmaceutical preparations for the treatment of viral diseases; Pharmaceutical preparations for the treatment of viral infections; Pharmaceutical preparations for the treatment of inflammation; Pharmaceutical preparations for treating chemical imbalances; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating hypoglycemia; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for treating sunburn; Pharmaceutical preparations for wounds; Pharmaceutical preparations, namely, anticoagulants; Pharmaceutical preparations, namely, antidepressants; Pharmaceutical preparations, namely, antivirals; Pharmaceutical preparations, namely, elixirs for the treatment of cancer; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of cancer; Pharmaceutical products for the treatment of infectious diseases; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Pharmaceutical products for the treatment of viral diseases; Pharmaceutical products for treating respiratory diseases; Pharmaceutical skin lotions; Anti-diabetic pharmaceuticals; Anti-epileptic pharmaceutical preparations; Balms for pharmaceutical purposes; Dermatological pharmaceutical products; Digestives for pharmaceutical purposes; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of tablets that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Plant extracts for pharmaceutical purposes; Plant extracts for medical, veterinary and pharmaceutical purposes; Potassium preparations for pharmaceutical purposes; Yeast for pharmaceutical consumption | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 26, 2025 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| May 26, 2025 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Oct 22, 2024 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Sep 11, 2024 | TMBN | TTAB RELEASE CASE TO TRADEMARKS | — |
| Sep 11, 2024 | OP.T | OPPOSITION TERMINATED NO. 999999 | — |
| Sep 11, 2024 | OP.D | OPPOSITION DISMISSED NO. 999999 | — |
| Mar 28, 2023 | OP.I | OPPOSITION INSTITUTED NO. 999999 | — |
| Mar 28, 2023 | OPPF | OPPOSITION PAPERS RECEIVED AT TTAB | — |
| Feb 28, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Feb 28, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 8, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jan 23, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 21, 2023 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jan 21, 2023 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jan 21, 2023 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jan 21, 2023 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jan 13, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 5, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 2, 2022 | NWAP | NEW APPLICATION ENTERED | — |